



HEALTHCARE

Biotech Exit Strategies

Delivering value to investors in a challenging funding market

By Steven Seget

Steven Seget

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA from the London Business School. sseget@delphipharma.com

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the portfolio management, licensing and pricing and reimbursement functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. www.delphipharma.com

Copyright © 2009 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Biotech exit strategies

Executive Summary	10	
An introduction to biotech exit strategies	10	
Biotech exit trends	11	
IPO exit strategies	12	
M&A exit strategies	13	
Alliances and licensing exit strategies	14	
Building the path to exit	15	
Chapter 1	An introduction to biotech exit strategies	18
Summary		18
Introduction		19
The biotechnology funding lifecycle		20
IPO as an exit strategy		21
M&A as an exit strategy		21
Alliance/licensing as an exit strategy		22
Developing a path to exit		22
Chapter 2	Biotech exit trends	26
Summary		26
Introduction		27
Biotechnology funding trends		27
IPOs are down and will be for a while...		30
M&A is up...		31
Licensing is down slightly but still delivering value...		31
Biotechnology productivity trends		34

Biotech exit strategy trends	36
IPO trends	37
M&A trends	37
Alliances/licensing trends	38
Future exit strategy trends	41
Reverse mergers	41
Creative financing	42
The quasi-public corporation	43
Chapter 3	IPO exit strategies
	46
Summary	46
Introduction	47
The traditional exit strategy	47
Key benefits	49
Key challenges	50
Case study insights	50
Bioheart – 2008’s only US IPO	51
MolMed – 2008’s biggest IPO	52
Acorda – Two rounds of follow-on offerings in 2008	52
Talecris Biotherapeutics –IPO registration leads to acquisition	53
Alimera Sciences – Proposed IPO withdrawn	54
Key success factors	55
Timing is everything...	56
Products, products, products...	56
Commercial validation from partners and investors...	57
Corporate management talent...	57
Chapter 4	M&A exit strategies
	60
Summary	60
Introduction	61
The emerging exit strategy	61
Key benefits	63
Key challenges	64
Case study insights	65
Piramed – 2008 big pharma acquisition	65
U3 Pharma – 2008 Japanese pharma acquisition	66
OncoGenex Technologies – 2008 reverse merger	67
IDM Pharma – Reverse merger at risk of delisting	68
Protein Sciences – 2008 terminated biotech acquisition	69

Key success factors	71
Clinical validation...	71
Commercial potential...	71
Existing relationships...	72
Committed management...	72

Chapter 5 Alliances and licensing exit strategies 74

Summary	74
Introduction	75
The part exit strategy	75
Key benefits	77
Key challenges	78
Case study insights	79
Adnexus – Laying the tracks for an eventual buy-out	79
MacroGenics – Generating a funding catalyst	81
ChemoCentryx – Blockbuster strategic alliance, but no IPO	82
Anacor – Key partnerships but no IPO	84
Phenomix – Licensing instead of IPO	86
Key success factors	87
The right deal with the right partner at the right time...	87
Reinforcing the long-term exit strategy...	87
Creating, not limiting opportunities...	88

Chapter 6 Building the path to exit 90

Summary	90
Introduction	91
Defining the objectives	91
Asset-level exit	92
Enterprise-level exit	93
Keeping options open	93
Setting the parameters	94
Clinical	95
Commercial	96
Financial	96
Building on success	97
Responding to failure	98

Chapter 7	Appendix	102
Research sources		102
Bibliography		102

List of Figures

Figure 1.1:	The biotechnology funding lifecycle	20
Figure 1.2:	The biotechnology path to exit	23
Figure 2.3:	Global biotech funding trends (US\$bn), 2004-08	28
Figure 2.4:	Global IPO trends, 2004-08	30
Figure 2.5:	Biotech M&A trends, 2004-08	31
Figure 2.6:	Biotech alliance and licensing deal trends, 2004-08	32
Figure 2.7:	Biotech alliance and licensing value trends (US\$m), 2004-08	33
Figure 2.8:	New product approvals – leading biotechs versus leading pharma, 2004-08	35
Figure 2.9:	R&D productivity – leading biotechs versus leading pharma (US\$bn), 2004-08	36
Figure 2.10:	Number and value (US\$bn) of US biotech IPOs, 2004-08	37
Figure 2.11:	Number and value (US\$bn) of M&As, 2004-08	38
Figure 2.12:	Biotech alliances and licensing trends (US\$m), 2004-08	39
Figure 2.13:	Biotech alliances and licensing trends by development stage, 2004-08	40
Figure 3.14:	Average IPO exit values in US (US\$m), 2004-08	48
Figure 4.15:	Average major biotech M&A exit values, 2004-08	62
Figure 5.16:	Average licensing/alliance part exit values (US\$m), 2004-08	76
Figure 6.17:	Defining biotech exit objectives	92
Figure 6.18:	Setting biotech exit parameters	95

List of Tables

Table 3.1:	Leading US IPOs (US\$m), 2004-08	47
Table 3.2:	Bioheart profile: 2008's only US IPO	51
Table 3.3:	MolMed profile: 2008's biggest IPO	52
Table 3.4:	Acorda profile: 2008's only double follow-on offering	53
Table 3.5:	Talecris Biotherapeutics profile: 2008 proposed IPO leads to M&A	54
Table 3.6:	Alimera Sciences profile: 2008 proposed IPO withdrawn	55
Table 4.7:	Leading private biotech M&A deals, 2006-08	61
Table 4.8:	Piramed profile: 2008 big pharma M&A exit	66
Table 4.9:	U3 Pharma profile: 2008 Japanese pharma M&A exit	67
Table 4.10:	OncoGenex Technologies profile: 2008 reverse merger	68
Table 4.11:	IDM Pharma profile: reverse merger at risk of delisting	69
Table 4.12:	Protein Sciences profile: terminated 2008 biotech M&A exit	70
Table 5.13:	Leading private biotech licensing and alliance deals (US\$bn), 2006-08	75
Table 5.14:	Adnexus profile: strategic alliance leading to 2007 M&A exit	80
Table 5.15:	MacroGenics profile: strategic alliance as a 2008 funding catalyst	81
Table 5.16:	ChemoCentryx profile: strategic alliance but no 2008 IPO	83
Table 5.17:	Anacor profile: two key partnerships but no 2008 IPO	85
Table 5.18:	Phenomix profile: 2008 strategic alliance instead of IPO	86